Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

Meyers DE, Bryan PM, Banerji S, Morris DG.

Curr Oncol. 2018 Aug;25(4):e324-e334. doi: 10.3747/co.25.3976. Epub 2018 Aug 14. Review.

2.

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.

Mostafa AA, Meyers DE, Thirukkumaran CM, Liu PJ, Gratton K, Spurrell J, Shi Q, Thakur S, Morris DG.

Cancers (Basel). 2018 Jun 15;10(6). pii: E205. doi: 10.3390/cancers10060205.

3.

Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.

Meyers DE, Hill WF, Suo A, Jimenez-Zepeda V, Cheng T, Nixon NA.

Exp Hematol Oncol. 2018 Mar 20;7:6. doi: 10.1186/s40164-018-0098-5. eCollection 2018.

4.

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Meyers DE, Thakur S, Thirukkumaran CM, Morris DG.

Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0. Review.

5.

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.

Meyers DE, Wang AA, Thirukkumaran CM, Morris DG.

Front Oncol. 2017 Jun 6;7:114. doi: 10.3389/fonc.2017.00114. eCollection 2017. Review.

6.

End-of-Life Decisions and Palliative Care in Advanced Heart Failure.

Meyers DE, Goodlin SJ.

Can J Cardiol. 2016 Sep;32(9):1148-56. doi: 10.1016/j.cjca.2016.04.015. Epub 2016 May 13. Review.

PMID:
27568873
7.

Protocol-Driven Allied Health Post-Discharge Transition Clinic to Reduce Hospital Readmissions in Heart Failure.

Donaho EK, Hall AC, Gass JA, Elayda MA, Lee VV, Paire S, Meyers DE.

J Am Heart Assoc. 2015 Dec 23;4(12). pii: e002296. doi: 10.1161/JAHA.115.002296.

8.

Present-Day Hospital Readmissions after Left Ventricular Assist Device Implantation: A Large Single-Center Study.

Hernandez RE, Singh SK, Hoang DT, Ali SW, Elayda MA, Mallidi HR, Frazier OH, Meyers DE.

Tex Heart Inst J. 2015 Oct 1;42(5):419-29. doi: 10.14503/THIJ-14-4971. eCollection 2015 Oct.

9.

Cardiac manifestations of mitochondrial disorders.

Meyers DE, Basha HI, Koenig MK.

Tex Heart Inst J. 2013;40(5):635-6. No abstract available.

10.

Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management.

Meyers DE, Basha HI, Koenig MK.

Tex Heart Inst J. 2013;40(4):385-94. Review.

11.

Trauma in patients with continuous-flow left ventricular assist devices.

Sarsam SH, Meyers DE, Civitello AB, Agunanne EE, Odegaard P, Cohn WE, Frazier OH.

Am J Cardiol. 2013 Nov 1;112(9):1520-2. doi: 10.1016/j.amjcard.2013.07.008. Epub 2013 Aug 30.

PMID:
23993120
12.

Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.

Meyers DE, Adu-Gyamfi B, Segura AM, Buja LM, Mallidi HR, Frazier OH, Rice L.

Am J Transplant. 2013 Oct;13(10):2730-3. doi: 10.1111/ajt.12391. Epub 2013 Aug 5.

13.

Exercise training in recently hospitalized heart failure patients enrolled in a disease management programme: design of the EJECTION-HF randomized controlled trial.

Mudge AM, Denaro CP, Scott AC, Atherton JJ, Meyers DE, Marwick TH, Adsett JA, Mullins RW, Suna JM, Scuffham PA, O'Rourke PK.

Eur J Heart Fail. 2011 Dec;13(12):1370-5. doi: 10.1093/eurjhf/hfr139. Epub 2011 Nov 6.

14.

Characterisation of lead precipitate following uptake by roots of Brassica juncea.

Meyers DE, Kopittke PM, Auchterlonie GJ, Webb RI.

Environ Toxicol Chem. 2009 Nov;28(11):2250-4. doi: 10.1897/09-131.1.

PMID:
19508110
15.

Uptake and localisation of lead in the root system of Brassica juncea.

Meyers DE, Auchterlonie GJ, Webb RI, Wood B.

Environ Pollut. 2008 May;153(2):323-32. doi: 10.1016/j.envpol.2007.08.029. Epub 2008 Jan 11.

PMID:
18191314
16.

The role of growth hormone replacement in a growth hormone deficient patient with underlying cardiomyopathy and severe congestive heart failure.

Meyers DE, Maddicks-Law J, Seaton DM, Galbraith AJ, Cuneo RC.

J Heart Lung Transplant. 2005 Jan;24(1):110-4.

PMID:
15653391
17.

Controversies regarding the effects of growth hormone on the heart.

Meyers DE, Cuneo RC.

Mayo Clin Proc. 2003 Dec;78(12):1521-6. Review.

PMID:
14661681
18.
19.

In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.

Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM.

Cancer Res. 1995 Mar 15;55(6):1321-7.

20.

Fast pre-potential generation in rat hippocampal CA1 pyramidal neurons.

Turner RW, Meyers DE, Barker JL.

Neuroscience. 1993 Apr;53(4):949-59.

PMID:
8506028
22.

Ionic currents of morphologically distinct peptidergic neurons in defined culture.

Meyers DE, Graf RA, Cooke IM.

J Neurophysiol. 1992 May;67(5):1301-15.

PMID:
1597714
23.
24.

GABAB receptors in the cat spinal cord.

Lev-Tov A, Meyers DE, Burke RE.

J Basic Clin Physiol Pharmacol. 1990 Jan-Dec;1(1-4):87-94. Review. No abstract available.

PMID:
1964803
25.

Localization of tetrodotoxin-sensitive field potentials of CA1 pyramidal cells in the rat hippocampus.

Turner RW, Meyers DE, Barker JL.

J Neurophysiol. 1989 Dec;62(6):1375-87.

PMID:
2557391
26.
27.
30.

Phasic modulation of short latency cutaneous excitation in flexor digitorum longus motoneurons during fictive locomotion.

Schmidt BJ, Meyers DE, Fleshman JW, Tokuriki M, Burke RE.

Exp Brain Res. 1988;71(3):568-78.

PMID:
3416970
33.
34.

Steroid modulation of GABAA receptor-coupled Cl- conductance.

Barker JL, Harrison NL, Meyers DE, Majewska MD.

Clin Neuropharmacol. 1986;9 Suppl 4:392-4. No abstract available.

PMID:
2436770
35.
41.
42.

Supplemental Content

Loading ...
Support Center